Tony Luongo, MD
Urology · Boston, MANPI 1164520417
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Johnson & Johnson at 40.9% of the total. Reporting peaked in 2019 at $88,388 and has fallen 78.4% since, to $19,127 in 2025. Among urology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 347 payments — averaging $762.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$108K
- Astellas Pharma US Inc$81K
- Pfizer$33K
- Medtronic$11K
- Myovant Sciences Inc.$11K
- C. R. Bard, Inc. & Subsidiaries$6K
- plus $16K from 32 others
Across 4 payments — averaging $9528.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$38K
What the payments were for
- Consulting fees$75,00328%
- Speaking & faculty fees$149,07056%
- Travel & lodging$33,96213%
- Food & beverage$6,5412%
- Education$910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 102 | $108,196 |
| Astellas Pharma US Inc | 96 | $80,809 |
| Pfizer | 37 | $32,601 |
| Medtronic(2 entities) | 13 | $10,649 |
| Myovant Sciences Inc. | 8 | $10,616 |
| C. R. Bard, Inc. & Subsidiaries | 9 | $5,720 |
| Bard Peripheral Vascular, Inc. | 3 | $5,350 |
| Gyrus ACMI, Inc. | 2 | $3,050 |
| Bayer | 4 | $1,841 |
| Olympus Medical Systems Corporation | 1 | $1,620 |
| Ambu A/s | 1 | $750 |
| Sun Pharmaceutical Industries Inc. | 1 | $500 |
| Tersera Therapeutics LLC | 2 | $487 |
| Sanofi | 1 | $350 |
| BD | 1 | $340 |
| Ferring Pharmaceuticals Inc. | 7 | $178 |
| Tolmar Pharmaceuticals, Inc. | 7 | $143 |
| Urogen Pharma, Inc. | 4 | $140 |
| 180 Medical, Inc. | 5 | $138 |
| Telix Pharmaceuticals | 3 | $130 |
| Antares Pharma, Inc. | 2 | $112 |
| Boston Scientific | 4 | $107 |
| Merck | 4 | $104 |
| AbbVie(2 entities) | 4 | $95 |
| Blue Earth Diagnostics | 4 | $94 |
| Progenics Pharmaceuticals, Inc. | 3 | $83 |
| Coloplast | 4 | $72 |
| Immunitybio, Inc. | 2 | $63 |
| Convatec Inc. | 1 | $49 |
| Urovant Sciences Inc | 2 | $43 |
| Endo Pharmaceuticals Inc. | 2 | $41 |
| Intuitive Surgical | 1 | $40 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| Teleflex LLC | 1 | $37 |
| Tolmar, Inc. | 1 | $27 |
| Metuchen Pharmaceuticals | 1 | $20 |
| Rochester Medical Corporation | 1 | $19 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$264,667 in reported general payments places this provider in the 95th percentile of 327 urology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 59 | $32,939 |
| GemtesaVibegron | 14 | $10,409 |
| Tamsulosin Hcl | 241 | $3,476 |
| Finasteride | 134 | $1,820 |
| Dutasteride | 24 | $1,374 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 13 | $467 |
| CefuroximeCefuroxime Axetil | 25 | $111 |
| Ciprofloxacin Hcl | 12 | $76 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $80,809 | $32,93959 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $38 | $10,40914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 327 urology providers in Massachusetts.
Other urology in Boston
- Christopher CutieBoston$3.5M
- Brian EisnerBoston$424K
- Stephen DretlerBoston$298K
- Ricardo MunarrizBoston$118K
- Mehrdad AlemozaffarBoston$95K
- Adam KibelBoston$92K
- Ruslan KoretsBoston$86K
- Adam FeldmanBoston$74K
- William BoysenBoston$56K
- Shahin TabatabaeiBoston$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.